01 Shift from Aortic Only Treatments to Comprehensive Valve Therapy A major trend in the transcatheter heart valve market is evolving beyond aortic valve replacement to include treatments for mitral and tricuspid valve diseases. In April 2024, Abbott received FDA approval for its TriClip device, a transcatheter edge-to-edge repair system designed to treat tricuspid regurgitation (TR). Such approval marked an advancement in the treatment of TR, a condition involving a leaky tricuspid valve, offering patients a safer, less invasive treatment option that reduced recovery time and hospital stay.
02 Shift from Manual Procedures to Image-Guided and Robotic-Assisted THV Interventions A major trend in the transcatheter heart valve (THV) market is the transition from traditional, manually guided procedures to advanced, image-guided and robotic-assisted interventions. Recently, Medtronic announced the successful completion of the first commercial transcatheter heart valve procedure using the Hugo robotic-assisted surgery system in Korea at Seoul National University Hospital. Such a trend reflected the broader global movement towards incorporating robotic-assisted technologies in surgical practices, aiming to improve patient outcomes and operational efficiencies.
01 Advancements in Transcatheter Heart Valve (THV) Technologies The driver for the growth of the global market is the continuous innovation in valve design, delivery systems, and procedural techniques. For example, in August 2024, Boston Scientific announced that its ACURATE Prime Aortic Valve System received CE Mark approval. This advanced transcatheter aortic valve replacement (TAVR) system featured a self-expanding design and a refined deployment mechanism, enhancing the accuracy of valve positioning. Such advancements enhanced the market growth by improving procedural outcomes and expanding treatment options for patients with heart valve diseases.
01 High Cost of Transcatheter Heart Valve Procedures A restraint in the transcatheter heart valve market is the high cost associated with procedures, such as transcatheter aortic valve replacement (TAVR). As per the article published in the American Heart Association, Inc., commercial prices for cardiac valve surgery ranged from USD 27,550 to USD 176,321. Such a high cost barrier created a challenge for healthcare providers and patients, particularly in regions with limited healthcare budgets. It underscored the demand for cost-efficient solutions and potential policy interventions to make these lifesaving procedures more accessible to a larger segment of the population.
01 Expansion of Treatment Indications An opportunity in the transcatheter heart valve market is the expansion of treatment indications beyond traditional patient populations, particularly for conditions such as aortic regurgitation (AR). For example, in August 2025, the U.S. Food and Drug Administration (FDA) approved the use of transcatheter aortic valve replacement (TAVR) for patients with symptomatic severe aortic regurgitation who are at high or extreme risk for open heart surgery. Such factors opened up a new patient segment for TAVR procedures, which further supported in expanding the potential market.
March 2026 Edwards Lifesciences expanded its transcatheter heart valve portfolio with advanced valve technologies designed to improve minimally invasive cardiac procedures and patient outcomes.
September 2025 Medtronic introduced enhanced transcatheter heart valve solutions featuring improved delivery systems and design innovations for structural heart disease treatments.
May 2025 Abbott expanded its structural heart portfolio with new transcatheter valve technologies focused on improving treatment options for patients with heart valve disorders.